- Company
- Only 14% of Pharmas plan to increase jobs due to COVID-19
- by Chon, Seung-Hyun Jan 4, 2022 05:56am
- The prolonged COVID-19 pandemic is expected to bring personnel reshuffling changes to the pharmaceutical and biopharmaceutical industry. CEOs in the pharma industry said that they plan to maintain or reduce the size of new employments in their companies. In addition, 7 out of 10 CEOs predicted that while the companies will maintain the num
- Policy
- Recovery Action held by the Legislation/Judiciary Committee
- by Lee, Jeong-Hwan Jan 4, 2022 05:56am
- The recovery system of drug prices bill, which drew attention from the government and domestic and foreign pharmaceutical companies, has been held by the National Assembly's Legislation and Judiciary Committee and is in trouble to deal with it. As it was excluded from the Legislation and Judiciary Committee agenda again during the extraordin
- Policy
- President Moon "will make all efforts to return to normalcy"
- by Lee, Jeong-Hwan Jan 4, 2022 05:56am
- During his 2022 New Year’s address, President Moon Jae-in expressed his gratitude and respect to the medical professionals and personnel working to contain and prevent COVID-19 and restressed the excellence of Korea’s disease control and prevention system. The president also expressed his ambition to achieve complete recovery of the peo
- Company
- 2/3 of CEOs plan to continue 'contactless' business activity
- by Kim, Jin-Gu Jan 4, 2022 05:56am
- Three years into the COVID-19 pandemic, 3 out of 4 CEOs from pharmaceutical and biopharmaceutical companies expect their company’s non-face-to-face business activities to expand further this year. The CEOs have also announced plans to maintain or reinforce their non-face-to-face business activities that settled as the ‘new normal’ in
- Policy
- Minister Kwon said he would develop vaccines and txs
- by Kim, Jung-Ju Jan 4, 2022 05:55am
- Minister of Health and Welfare said he will foster the biohealth industry by investing in building a global bio-human resource training hub, developing vaccines and treatments, creating a "K-Global" vaccine fund and revitalizing the use of domestic medical devices in 2022. Minister Kwon issued a New Year's address today (31st) and explained t
- Policy
- Additional contracts for COVID-19 PO tx are under discussion
- by Kim, Jung-Ju Jan 4, 2022 05:55am
- The government is pushing for additional purchases of oral COVID-19 treatments separately from existing contracts.The KDCA announced its 2022 work plan today (30th) under the theme of "COVID-19 Disease Control and Prevention Response and National Health Support." Authorities plan to strengthen severe prevention by introducing oral treatmen
- Company
- Strengthening sales is the top priority in competitiveness
- by Chon, Seung-Hyun Jan 3, 2022 05:57am
- Three out of five CEOs of pharmaceutical companies pointed to "strengthening sales and marketing capabilities" as the most important management strategy to expand competitiveness in the post-Corona era. The view is that it is urgent to establish an effective sales strategy due to rapid changes in the market environment. More than half of the
- Company
- Expectations rise for prescription of tumor-agnostic drugs
- by Eo, Yun-Ho Jan 3, 2022 05:56am
- Preparations to prescribe`tumor-agnostic' anticancer drugs in the field are well underway. According to industry sources, Bayer Korea’s neurotrophic tyrosine receptor kinase (NTRK) inhibitor Vitrakvi (larotrectinib) has passed the drug committee (DCs) of general hospitals in Korea including the Seoul National University Hospital. Thu
- Product
- Is the price of Paxlovid reasonable?
- by Jan 3, 2022 05:55am
- On the 27th, Paxlovid, an oral treatment for COVID-19, was approved for EUA by the MFDS, and the Pharmaceutical Association for Health Society asked questions about the insolvency and effectiveness of the screening process on the 30th. The Health Pharmaceutical Association said, "Paxlovid is expected to be used in patients with high risk amon
- Company
- Samsung Biologics denies rumors of Biogen's acquisition
- by Jan 3, 2022 05:55am
- Biogen shares fluctuated on reports that Samsung Group is trying to acquire U.S. pharmaceutical company Biogen for 50 trillion won. Samsung said, "It's not true."Some media recently observed that Samsung Group has begun negotiations after a preliminary review to acquire Biogen. The acquisition is expected to reach 50 trillion won. Shortly
